Biofil Chemicals & Pharmaceuticals Limited (NSE:BIOFILCHEM) — Market Cap & Net Worth
Market Cap & Net Worth: Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM)
Biofil Chemicals & Pharmaceuticals Limited (NSE:BIOFILCHEM) has a market capitalization of $6.29 Million (Rs581.46 Million) as of June 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #28119 globally and #1571 in its home market, demonstrating a -1.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biofil Chemicals & Pharmaceuticals Limited's stock price Rs35.73 by its total outstanding shares 16273800 (16.27 Million). Review BIOFILCHEM liabilities breakdown to assess the company's total debt and financial obligations.
Biofil Chemicals & Pharmaceuticals Limited Market Cap History: 2017 to 2026
Biofil Chemicals & Pharmaceuticals Limited's market capitalization history from 2017 to 2026. Data shows growth from $3.08 Million to $6.23 Million (5.60% CAGR).
Biofil Chemicals & Pharmaceuticals Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biofil Chemicals & Pharmaceuticals Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Biofil Chemicals & Pharmaceuticals Limited's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.06x
Biofil Chemicals & Pharmaceuticals Limited's market cap is 1.06 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $3.08 Million | $134.54 Million | $17.94 Million | 0.02x | 0.17x |
| 2018 | $1.21 Million | $123.60 Million | $4.71 Million | 0.01x | 0.26x |
| 2019 | $3.63 Million | $231.29 Million | $4.82 Million | 0.02x | 0.75x |
| 2020 | $30.68 Million | $296.90 Million | $12.07 Million | 0.10x | 2.54x |
| 2021 | $10.65 Million | $357.50 Million | $12.41 Million | 0.03x | 0.86x |
| 2022 | $9.71 Million | $223.82 Million | $6.98 Million | 0.04x | 1.39x |
| 2023 | $9.53 Million | $300.35 Million | $5.60 Million | 0.03x | 1.70x |
| 2024 | $10.11 Million | $400.35 Million | $7.09 Million | 0.03x | 1.43x |
| 2025 | $5.91 Million | $334.02 Million | $5.58 Million | 0.02x | 1.06x |
Competitor Companies of BIOFILCHEM by Market Capitalization
Companies near Biofil Chemicals & Pharmaceuticals Limited in the global market cap rankings as of June 19, 2026.
Key companies related to Biofil Chemicals & Pharmaceuticals Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #631 globally with a market cap of $43.86 Billion USD ( CN¥299.75 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #634 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.27 |
| #631 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.86 Billion | CN¥46.99 |
| #634 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Biofil Chemicals & Pharmaceuticals Limited Historical Marketcap From 2017 to 2026
Between 2017 and today, Biofil Chemicals & Pharmaceuticals Limited's market cap moved from $3.08 Million to $ 6.23 Million, with a yearly change of 5.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs6.23 Million | +5.45% |
| 2025 | Rs5.91 Million | -41.57% |
| 2024 | Rs10.11 Million | +6.09% |
| 2023 | Rs9.53 Million | -1.90% |
| 2022 | Rs9.71 Million | -8.76% |
| 2021 | Rs10.65 Million | -65.29% |
| 2020 | Rs30.68 Million | +746.12% |
| 2019 | Rs3.63 Million | +200.73% |
| 2018 | Rs1.21 Million | -60.86% |
| 2017 | Rs3.08 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Biofil Chemicals & Pharmaceuticals Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.29 Million USD |
| MoneyControl | $6.29 Million USD |
| MarketWatch | $6.29 Million USD |
| marketcap.company | $6.29 Million USD |
| Reuters | $6.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biofil Chemicals & Pharmaceuticals Limited
Biofil Chemicals and Pharmaceuticals Limited engages in manufacturing and trading of pharmaceuticals in India. It operates through Pharmaceutical and Chemical divisions. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and … Read more